| 000 | 05742cam a2200841Ii 4500 | ||
|---|---|---|---|
| 001 | ocn826637765 | ||
| 003 | OCoLC | ||
| 005 | 20171224114146.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 130204t20132013gw ac ob 001 0 eng d | ||
| 040 |
_aDG1 _beng _erda _epn _cDG1 _dEBLCP _dN$T _dMHW _dYDXCP _dCOO _dIDEBK _dE7B _dNOC _dOCLCF _dIUL _dSCB _dOCLCQ _dCDX _dNKT _dOCLCQ |
||
| 019 |
_a828869678 _a828896125 _a961601655 _a962705463 |
||
| 020 |
_a9783527651085 _q(electronic bk.) |
||
| 020 |
_a352765108X _q(electronic bk.) |
||
| 020 |
_a9783527651115 _q(electronic bk.) |
||
| 020 |
_a352765111X _q(electronic bk.) |
||
| 020 |
_a9781299241206 _q(MyiLibrary) |
||
| 020 |
_a1299241204 _q(MyiLibrary) |
||
| 020 | _z9783527330737 | ||
| 020 | _z3527330739 | ||
| 029 | 1 |
_aAU@ _b000050562533 |
|
| 029 | 1 |
_aAU@ _b000053030546 |
|
| 029 | 1 |
_aDKDLA _b820120-katalog:000655918 |
|
| 029 | 1 |
_aNLGGC _b382514440 |
|
| 029 | 1 |
_aNZ1 _b15340091 |
|
| 029 | 1 |
_aDEBBG _bBV043395341 |
|
| 035 |
_a(OCoLC)826637765 _z(OCoLC)828869678 _z(OCoLC)828896125 _z(OCoLC)961601655 _z(OCoLC)962705463 |
||
| 037 |
_a455370 _bMIL |
||
| 050 | 4 |
_aRM301.25 _b.A53 2013 |
|
| 072 | 7 |
_aMED _x023000 _2bisacsh |
|
| 072 | 7 |
_aMED _x058170 _2bisacsh |
|
| 072 | 7 |
_aMED _x071000 _2bisacsh |
|
| 072 | 7 |
_aMED _x072000 _2bisacsh |
|
| 072 | 7 |
_aHEA _2eflch |
|
| 082 | 0 | 4 |
_a615.1/9 _223 |
| 049 | _aMAIN | ||
| 245 | 0 | 0 |
_aAnalogue-based drug discovery III / _cedited by János Fischer, C. Robin Ganellin, David P. Rotella. |
| 246 | 3 | _aAnalogue-based drug discovery 3 | |
| 246 | 3 | _aAnalog-based drug discovery III | |
| 264 | 1 |
_aWeinheim : _bWiley-VCH, _c[2013] |
|
| 264 | 4 | _c©2013 | |
| 300 |
_a1 online resource (xviii, 385 pages) : _billustrations, portraits |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 588 | 0 | _aOnline resource; title page from PDF title page (viewed June 30, 2014). | |
| 505 | 0 | 0 |
_tGeneral Aspects. Pioneer and Analogue Drugs / _rJanos Fischer, C Robin Ganellin, David P Rotella -- _tCompetition in the Pharmaceutical Drug Development / _rChristian Tyrchan, Fabrizio Giordanetto -- _tMetabolic Stability and Analogue-Based Drug Discovery / _rAmit S Kalgutkar, Antonia F Stepan -- _tUse of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders / _rMark L Peterson, Hamid Hoveyda, Graeme Fraser, Eric Marsault, Rene Gagnon -- _tDrug Classes. The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes / _rA Ganesan -- _tThienopyridyl and Direct-Acting P2Y Receptor Antagonist Antiplatelet Drugs / _rJoseph A Jakubowski, Atsuhiro Sugidachi -- _tSelective Estrogen Receptor Modulators / _rAmarjit Luniwal, Rachael Jetson, Paul Erhardt -- _tDiscovery of Nonpeptide Vasopressin V2 Receptor Antagonists / _rKazumi Kondo, Hidenori Ogawa -- _tThe Development of Cysteinyl Leukotriene Receptor Antagonists / _rPeter R Bernstein -- _tCase Studies. The Discovery of Dabigatran Etexilate / _rNorbert Hauel, Andreas Clemens, Herbert Nar, Henning Priepke, Joanne van Ryn, Wolfgang Wienen -- _tThe Discovery of Citalopram and Its Refinement to Escitalopram / _rKlaus P Bogeso, Connie Sanchez -- _tTapentadol : From Morphine and Tramadol to the Discovery of Tapentadol / _rHelmut Buschmann -- _tNovel Taxanes: Cabazitaxel Case Study / _rHerve Bouchard, Dorothee Semiond, Marie-Laure Risse, Patricia Vrignaud -- _tDiscovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design / _rSrikanth Venkatraman, Andrew Prongay, George F Njoroge -- _tA New-Generation Uric Acid Production Inhibitor: Febuxostat / _rKen Okamoto, Shiro Kondo, Takeshi Nishino. |
| 504 | _aIncludes bibliographical references and index. | ||
| 520 | _a"Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and--together with the previous volumes--constitutes the first systematic approach to drug analogue development"--Publisher's website. | ||
| 650 | 0 | _aDrug development. | |
| 650 | 7 |
_aMEDICAL _xDrug Guides. _2bisacsh |
|
| 650 | 7 |
_aMEDICAL _xNursing _xPharmacology. _2bisacsh |
|
| 650 | 7 |
_aMEDICAL _xPharmacology. _2bisacsh |
|
| 650 | 7 |
_aMEDICAL _xPharmacy. _2bisacsh |
|
| 650 | 7 |
_aDrug development. _2fast _0(OCoLC)fst00898670 |
|
| 655 | 4 | _aElectronic books. | |
| 655 | 7 |
_aElectronic books. _2local |
|
| 700 | 1 |
_aFischer, János, _eeditor. |
|
| 700 | 1 |
_aGanellin, C. R. _q(C. Robin), _eeditor. |
|
| 700 | 1 |
_aRotella, David P., _eeditor. |
|
| 776 | 0 | 8 |
_iPrint version: _tAnalogue-based drug discovery III. _dWeinheim : Wiley-VCH, [2013] _z9783527330737 _w(OCoLC)825555931 |
| 856 | 4 | 0 |
_uhttp://onlinelibrary.wiley.com/book/10.1002/9783527651085 _zWiley Online Library |
| 938 |
_aCoutts Information Services _bCOUT _n24876696 _c130.00 GBP |
||
| 938 |
_aEBL - Ebook Library _bEBLB _nEBL1123660 |
||
| 938 |
_aebrary _bEBRY _nebr10662582 |
||
| 938 |
_aEBSCOhost _bEBSC _n542882 |
||
| 938 |
_aIngram Digital eBook Collection _bIDEB _ncis24876696 |
||
| 938 |
_aYBP Library Services _bYANK _n9985301 |
||
| 938 |
_aYBP Library Services _bYANK _n10226219 |
||
| 938 |
_aYBP Library Services _bYANK _n10247713 |
||
| 994 |
_a92 _bDG1 |
||
| 999 |
_c12409 _d12409 |
||